Posted inGastroenterology news Oncology
MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling
A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing critical interferon-gamma-mediated antitumor responses.
